JAMDA
Volume 11, Issue 3 , Pages 211-221, March 2010

Thrombotic Risk and Immobility in Residents of Long-Term Care Facilities

  • Barbara J. Zarowitz, PharmD, BCPS, FCCP, CGP, FASCP

      Affiliations

    • Omnicare, Inc, Livonia, MI
    • Corresponding Author InformationAddress correspondence to Barbara J. Zarowitz, PharmD, BCPS, FCCP, CGP, FASCP, Omnicare, Inc., 33510 Schoolcraft Road, Livonia, MI 48150.
  • ,
  • Eric Tangalos, MD

      Affiliations

    • Mayo Clinic, Rochester, MN
  • ,
  • Allen Lefkovitz, PharmD, CGP, FASCP

      Affiliations

    • Omnicare, Inc, Livonia, MI
  • ,
  • Henry Bussey, PharmD, FCCP

      Affiliations

    • College of Pharmacy, University of Texas at Austin, Austin, TX
  • ,
  • Steven Deitelzweig, MD

      Affiliations

    • Department of Hospital Medicine, Ochsner Medical Center and Tulane University Medical College, New Orleans, LA
  • ,
  • Edith Nutescu, PharmD

      Affiliations

    • School of Pharmacy, University of Illinois, Chicago, IL
  • ,
  • Terrence O'Shea, PharmD, CGP, FASCP

      Affiliations

    • Omnicare, Inc, Livonia, MI
  • ,
  • Barbara Resnick, RNP

      Affiliations

    • University of Maryland, Baltimore, MD
  • ,
  • Arthur Wheeler, MD

      Affiliations

    • Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN

published online 08 February 2010.

Background

Hospitalized patients and residents of long-term care (LTC) facilities account for about 60% of all cases of venous thromboembolism (VTE), as incidence is correlated with increasing age, immobility, and underlying medical conditions. The primary aim of the study was to develop an evidence-based VTE risk stratification tool and definition of immobility for residents in LTC facilities.

Methods

Using the Delphi process, a panel of vascular thrombotic and geriatric experts reviewed and ranked statements of VTE risk and immobility derived from randomized controlled trials, meta-analyses, cohort trials, case-control trials, and case series to arrive at consensus for the importance of each statement. Rating was conducted before and during an on-site meeting following discussion. Statements rated high and very high were used to develop a VTE risk stratification and immobility tool.

Results

A total of 1165 publications related to VTE risk were identified from which 137 (12%) pertained to subjects with a median age of 60 years or older; 42 (31%) met study criteria. Eight (29.6%) of 79 publications pertaining to immobility met study criteria. There were 4 studies related to VTE risk and 1 to immobility that were rated as high quality. VTE risk factors were age older than 60 years, active cancer, acute infectious disease, catheter in a central vein, chronic obstructive pulmonary disease, dehydration, history of VTE, having a first-degree relative with VTE, heart failure, hypercoagulable state, immobility, inflammatory bowel disease, obesity, rheumatoid arthritis and treatment with erythroid stimulating agents to a hemoglobin value greater than 12 g/dL, aromatase inhibitor, hormone replacement therapy, megestrol acetate, or selective estrogen receptor modulators. Immobility was defined as the presence of at least 1 of the following: being bedridden or bedridden except for bathroom privileges, unable to walk at least 10 feet, recent reduction in ability to walk at least 10 feet for at least 72 hours, and having a lower limb cast.

Conclusions

A risk stratification tool for VTE and immobility was developed to assist clinicians in caring for residents of LTC facilities. A prospective trial is needed to validate the tool.

Keywords: Thrombosis, immobility, long-term care

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The literature evaluation, on-site meeting, travel to the meeting, and biostatistical support were supported by an investigator-initiated grant (DCLB-547377.1) from Sanofi-Aventis Pharmaceuticals, USA.

PII: S1525-8610(09)00409-5

doi:10.1016/j.jamda.2009.11.006

JAMDA
Volume 11, Issue 3 , Pages 211-221, March 2010